Results 131 to 140 of about 6,578,993 (340)

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review

American Journal of Hematology, EarlyView.
ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos, Sotirios Manganas, Charalampos Filippatos, Konstantinos Karamouzis, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios‐Athanasios Dimopoulos   +7 more
wiley   +1 more source

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. [PDF]

, 2010
The HOX genes encode a family of transcription factors that are dysregulated in several malignancies and have been implicated in oncogenesis and cancer cell survival.
Daniels, TR, Morgan, R, Neacato, II, Pandha, HS, Penichet, ML, Rodríguez, JA   +5 more
core   +1 more source

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

American Journal of Hematology, EarlyView.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin, Bruno Paiva, Irene M. Ghobrial, Salomon Manier   +3 more
wiley   +1 more source

Relapses, Comorbidities, and Predictors of Outcome in Anti‐GABAA Receptor Encephalitis

Annals of Neurology, EarlyView.
Objectives To characterize the magnetic resonance imaging (MRI) lesion dynamics, comorbidities, predictors of relapse, and outcomes in anti‐γ‐aminobutyric acid type A receptor (GABAAR) encephalitis, and assess the utility of LIM‐domain‐only‐protein 5 (LMO5) antibodies as tumor markers.
Claudia Papi, Chiara Milano, Laura Marmolejo, Ana Beatriz Serafim, Esther Aguilar, Mar Guasp, Elianet Fonseca, Mateus Mistieri Simabukuro, Raffaele Iorio, Yuki Fukami, Maria Lucia Schmitz Ferreira Santos, Takashi Miwa, Takashi Araga, Yuto Uchida, Masanori Kurihara, Satoshi Okada, Luz Victoria Garcia, Kenichi Kaida, Natalia Spinola Costa da Cunha, Alberto Vogrig, Florian Lamblin, Juna M. de Vries, Livia Almeida Dutra, Romana Höftberger, Maarten J. Titulaer, Jesús Planagumà, Lidia Sabater, Eugenia Martinez‐Hernandez, Thais Armangué, Francesc Graus, Takahiro Iizuka, Josep Dalmau, Marianna Spatola, Anti‐GABAAR encephalitis study group   +33 more
wiley   +1 more source

Multiple myeloma presenting with external ear canal mass [PDF]

, 2017
The manifestations of multiple myeloma are protean and related to bony osteolytic lesions, and to medullar and renal insufficiency. We report a patient who presented with otalgia as the inaugural symptom of multiple myeloma.
Abele, R., Allal, A. S., Dulguerov, P., Kurt, A.-M, Montandon, P., Quinodoz, D., Ruefenacht, D.   +6 more
core  

Identification Epitope on VP4 Protein of Senecavirus A Recognized by a Monoclonal Antibody

Animal Research and One Health, EarlyView.
This study aims to identify conserved antigenic epitopes on the SVA VP4 protein using monoclonal antibodies, providing valuable tools for further exploring its functions and developing detection methods. SVA VP4 protein was expressed in Escherichia coli and purified with High‐Affinity Ni‐Charged Resin FF.
Liang Meng, Xuyan Xiang, Xinyu Qi, Hanrong Zhou, Peiyu Xiao, Fandan Meng, Tongqing An, Haiwei Wang   +7 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Haematologica
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed.
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti   +7 more
doaj   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Science Translational Medicine, 2019
GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts. CARs to drive away multiple myeloma Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have ...
Eric L. Smith, Kimberly H. Harrington, M. Staehr, Reed Masakayan, Jon C Jones, T. Long, Khong Y. Ng, M. Ghoddusi, Terence J. Purdon, Xiuyan Wang, Trevor Do, M. Pham, Jessica M. Brown, C. F. de Larrea, E. Olson, Elizabeth Peguero, Pei Wang, Hong Liu, Yiyang Xu, Sarah C. Garrett-Thomson, S. Almo, H. Wendel, I. Rivière, Cheng Liu, Blythe Sather, R. Brentjens   +25 more
semanticscholar   +1 more source